Sundaram Hema, Huang Po-Han, Hsu Nai-Jen, Huh Chang Hun, Wu Woffles T L, Wu Yan, Cassuto Daniel, Kerscher Martina J, Seo Kyle Koo-Il
Dermatology, Cosmetic & Laser Surgery, Rockville, Md.; Huang PH Dermatology and Aesthetics, Kaohsiung, Taiwan; and Aesthetics Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Dermatological Clinic, Tainan, Taiwan; Seoul National University Bundang Hospital, Seoul, South Korea; Aesthetic Surgery and Laser Centre, Singapore, Singapore; Peking University First Hospital, Beijing, China; University of Modena, Modena, Italy; Division of Cosmetic Sciences, University of Hamburg, Hamburg, Germany; and Seoul National University Hospital, Seoul, South Korea.
Plast Reconstr Surg Glob Open. 2016 Dec 7;4(12):e872. doi: 10.1097/GOX.0000000000000507. eCollection 2016 Dec.
Botulinum toxin type A remains the most popular nonsurgical aesthetic treatment worldwide. Previous consensus statements have focused on Caucasians and on Koreans as generally representative of Asians. However, indications and dosages vary among different ethnic groups. This publication reports the results of a multidisciplinary, pan-Asian consensus focusing on incobotulinumtoxinA.
A consensus group of plastic surgeons and dermatologists from Asia, Europe, and the United States convened for a live meeting in Asia, followed by a questionnaire-based Delphi procedure. Treatment of Asians in both their native countries and countries of migration was discussed.
For most items, the group achieved a majority consensus. A number of treatment indications, strategies, and dosages were identified in Asians, which are distinct to those previously described for Caucasians due to differences in facial morphotypes, anatomy, and cultural expectations. The group also formulated position statements for intradermal botulinum toxin type A ("mesotoxin"), body shaping with the calves as a paradigm, and reduction of parotid glands. While Asians have previously been considered a homogeneous group for the purposes of aesthetic treatment, this publication considers regional variations. A new classification of Asian facial morphotypes is proposed to aid treatment planning and implementation.
This is the first pan-Asian consensus for aesthetic use of botulinum toxin type A. Its unique objective is to optimize treatment safety and efficacy for patients of complete or part-Asian ancestry in all regions. The recommendations for incobotulinumtoxinA may be extended with care to other botulinum toxin formulations.
A型肉毒毒素仍然是全球最受欢迎的非手术美容治疗方法。以往的共识声明主要关注白种人以及通常作为亚洲人代表的韩国人。然而，不同种族群体的适应症和剂量有所不同。本出版物报告了一项针对注射用A型肉毒毒素的多学科泛亚共识的结果。
来自亚洲、欧洲和美国的整形外科医生和皮肤科医生组成的共识小组在亚洲召开了一次现场会议，随后进行了基于问卷的德尔菲法程序。讨论了在亚洲人本国以及移民国家对他们的治疗。
对于大多数项目，该小组达成了多数共识。在亚洲人中确定了一些治疗适应症、策略和剂量，由于面部形态、解剖结构和文化期望的差异，这些与先前对白种人描述的不同。该小组还制定了关于皮内注射A型肉毒毒素（“微毒素”）、以小腿塑形为例的身体塑形以及腮腺缩小的立场声明。虽然以前在美容治疗方面亚洲人被视为一个同质群体，但本出版物考虑了区域差异。提出了一种新的亚洲面部形态分类，以帮助治疗计划的制定和实施。
这是第一项关于A型肉毒毒素美容用途的泛亚共识。其独特目标是优化所有地区完全或部分亚洲血统患者的治疗安全性和有效性。注射用A型肉毒毒素的建议可能需要谨慎地扩展到其他肉毒毒素制剂。
